Hutchison MediPharma pleasantly welcomes the newly joining of Dr. Zhenping Wu, a “veteran” in the field of pharmaceutics. With his solid background and fruitful experience, Dr. Zhenping’s joining will certainly infuse new blood to Hutchison MediPharma.
Dr. Wu has 17 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. His past positions include Senior Director of Pharmaceutical Sciences at Phenomix Corporation, a California based drug discovery and development company, Director of Pharmaceutical Development at Pfizer Global Research & Development in San Diego, California (formerly Agouron Pharmaceuticals), and Senior Scientist at Roche’s Palo Alto site. Dr. Wu led many development project teams and advanced numerous drug candidates into different phases of clinical development and commercialization. The candidates include Sutent, a new blockbuster anti-cancer drug for Pfizer.
Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine. He is the past Chairman and President of the Board of Sino-American Biotechnology and Pharmaceutical Association. He received a Colleague Recognition Award from Pfizer in 2003 for his work on the Sutent project, a Dean’s Scholar Award from the University of California at Irvine in the same year, and a Leadership Award from Sino-American Biotechnology and Pharmaceutical Association in 2008. Dr. Wu was the recipient of an American Heart Association Fellowship in 1990.
Hutchison MediPharma sincerely wishes a pleasant cooperation with Dr. Wu in the future.